Clinical Efficacy of Dengyin Naotong Capsule for Cognitive Impairment Related to Cerebral Small Vascular Disease

Objective: This study aims to investigate the clinical efficacy of Dengyin Naotong (DYNT) capsule for cognitive impairment related to cerebral small vascular disease (CSVS). Methods: Total of 105 patients with cognitive impairment related to CSVD hospitalized in Zibo Fifth People's Hospital from July 2021 to June 2023 were selected and randomly divided into control group (53 cases) and treatment group (52 cases). The patients in control group were treated with anti-arteriosclerosis, anti-platelet aggregation, nicergoline treatment, etc. while in treatment group combined with DYNT capsule on the basis of control group for 6 months both in the two groups. Before and after treatment, the Mini-mental State Examination (MMSE), Montreal Cognitive Assessment Scale (MoCA), Ability of Daily Living (ADL) score, Tinetti Balance and Gait Assessment Scale (POMA) score, Traditional Chinese Medicine Syndrome Scores (TCMSS), and the plasma levels of homocysteine (Hcy), C reactive protein (CRP) and D-dimer of patients were observed. Results: After treatment, the MMSE scores, MoCA scores ADL scores and POMA scores of patients increased significantly than those before treatment (PPPPPP<0.05). Conclusion: DYNT capsule has some clinical efficacy in the treatment of cognitive impairment related to CSVD.